100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
You Searched
₹455.6
Our Recommendation
Bilypsa 4mg Tablet 10s
576+ trust this
WHO GMP Certified
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
WHO GMP
Certified
15 Days Easy
Returns
Long Expiry
(>8 Months)
Delivery by
In Treatment of Noncirrhotic Non-Alcoholic Steatohepatitis : Noncirrhotic non-alcoholic steatohepatitis (NASH) is liver inflammation and damage caused by excess fat in the liver. Because of the damage, the liver doesn't work as well as it should. Vorxar Tablet reduces fat deposition thereby improving its overall functioning. In Treatment of Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease is a condition in which there is an increased buildup of fat in the liver. It affects people who drink little to no alcohol. Vorxar Tablet protects the liver and reduces the risk of liver failure. In Treatment of Diabetic dyslipidemia (high cholesterol in diabetes)Vorxar Tablet helps in the management of high cholesterol, as well as blood sugar levels in people with type 2 diabetes. It is mainly used in people whose cholesterol levels are not controlled by statin therapy alone. By controlling high cholesterol levels, Vorxar Tablet helps reduce the risk of heart diseases.show moreshow less
Side effects of Vorxar Tablet The majority of side effects typically do not necessitate medical intervention. and disappear as your body adjusts to the medicine. Doctor consultation is advised if they persist or if you�re worried about them Common side effects of Vorxar Flatulence Indigestion Abdominal distension Weakness Increased body temperature
How to use Vorxar Tablet Follow your doctor's guidance regarding the dose and duration of this medication. Ingest it without breaking or crushing. Do not chew, crush or break it. Vorxar Tablet can be taken it with or without food, although it's advisable to take it consistently at the same time.
How Vorxar Tablet works Vorxar Tablet contains Saroglitazar, a dual action peroxisome proliferator-activated receptor (PPAR) inhibitor that aids in the management of high cholesterol, especially triglycerides, as well as blood sugar levels in people with type 2 diabetes. It acts by a unique mechanism in which it reduces the synthesis and secretion of triglycerides (a type of lipid or cholesterol in blood). It also improves insulin sensitivity of the body for better utilization of the existing insulin and hence lowers the blood sugar levels.
Unsafe: Avoid consuming alcohol with Vorxar Tablet as it is deemed unsafe.
Vorxar Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Doctor consultation is advised.
Vorxar Tablet should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
Vorxar Tablet does not usually affect your ability to drive.
There is limited information available on the use of Vorxar Tablet in patients with kidney disease. Doctor consultation is advised.
There is limited information available on the use of Vorxar Tablet in patients with liver disease. Doctor consultation is advised.
If you forget a dose of Vorxar Tablet take it as soon as you remember. But if your next dose is near, skip the missed one and continue with your regular schedule. Avoid doubling up on doses to compensate for the missed one.
Off. Ashram Road, Ahmedabad - 380 009., Gujarat, India
Saroglitazar. Ahmedabad, India: Cadila Healthcare Limited; 2013 (13 Mar. 2019)
Rajesh NA, Drishya L, Ambati MMR, Narayanan AL, Alex M, R KK, Abraham JJ, Vijayakumar TM. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):61-67 (06 Aug. 2023)
Padole P, Arora A, Sharma P, et al. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):435-439 (06 Aug. 2023)
Padole P, Arora A, Sharma P, et al. Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. J Clin Exp Hepatol. 2022 Mar-Apr;12(2):435-439 (06 Aug. 2023)
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.